Onconetix, Inc. (ONCO)
0.6547
0.00 (0.00%)
USD |
NASDAQ |
Aug 25, 16:00
0.643
-0.01
(-1.79%)
After-Hours: 18:34
Onconetix Debt to Equity Ratio : 0.0139 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0139 |
| March 31, 2026 | 0.0247 |
| December 31, 2025 | 0.0031 |
| September 30, 2025 | 0.0493 |
| June 30, 2025 | 1.378 |
| March 31, 2025 | 2.181 |
| December 31, 2024 | 1.376 |
| September 30, 2024 | 0.3519 |
| June 30, 2024 | 0.5686 |
| March 31, 2024 | 0.3607 |
| December 31, 2023 | 0.1686 |
| Date | Value |
|---|---|
| September 30, 2023 | 1.262 |
| June 30, 2023 | 1.006 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| March 31, 2021 | |
| December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Aprea Therapeutics, Inc. | 0.00 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 16.43M |
| Total Liabilities (Quarterly) | 2.956M |
| Shareholders Equity (Quarterly) | 13.47M |
| Current Ratio | 2.214 |
| Net Debt Paydown Yield | 45.08% |